Get started
Author

Tina Catalano

OpenAlex ID: A5012174657
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2021 · Stephen M. Ansell, Michael B. Maris, et al. · Clinical Cancer Research · 205
PDF
CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
2021 · Krish Patel, Jeffrey A. Zonder, et al. · Blood · 30
Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim
2016 · Kalpna Desai, Tina Catalano, et al. · Clinical Pharmacology in Drug Development · 25
PDF
Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
2020 · Krish Patel, Radhakrishnan Ramchandren, et al. · Blood · 17
A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal
2017 · Christiane Querfeld, John A. Thompson, et al. · Blood · 17
Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
2021 · Steven M. Horwitz, James M. Foran, et al. · Blood · 11
Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial
2018 · Christiane Querfeld, John Thompson, et al. · Blood · 11
Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
2020 · Steven M. Horwitz, James M. Foran, et al. · Blood · 8
Abstract 3854: Preclinical characterization of a novel non-cyclic dinucleotide small molecule STING agonist with potent antitumor activity in mice
2019 · Zezhou Wang, Peter Dove, et al. · Cancer Research · 8
A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.
2017 · John A. Thompson, Oleg Akilov, et al. · Journal of Clinical Oncology · 8
Demonstration of Clinical Comparability of the Biosimilar Filgrastim to Neupogen, in Terms of Safety and Efficacy, in Healthy Volunteers and Patients Receiving Myelosuppressive Chemotherapy
2014 · Bernd Jilma, Agnieszka Jagiełło-Gruszfeld, et al. · European Oncology & Haematology · 8
Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.
2020 · Krish Patel, Michael B. Maris, et al. · Journal of Clinical Oncology · 7
Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial
2018 · Christiane Querfeld, John A. Thompson, et al. · European Journal of Cancer · 7
Development of a proposed biosimilar product based on the demonstration of physicochemical, pharmacologic and clinical similarity to pegfilgrastim.
2015 · Kalpna Desai, Stephen Brokx, et al. · Journal of Clinical Oncology · 1
Supplemental Figure 1 from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2023 · Stephen M. Ansell, Michael B. Maris, et al.
Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2023 · Stephen M. Ansell, Michael B. Maris, et al.
Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2023 · Stephen M. Ansell, Michael B. Maris, et al.
Supplemental Figure 1 from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2023 · Stephen M. Ansell, Michael B. Maris, et al.
PDF
Abstract 3854: Preclinical characterization of a novel non-cyclic dinucleotide small molecule STING agonist with potent antitumor activity in mice
2019 · Zezhou Wang, Peter Dove, et al. · Experimental and Molecular Therapeutics
Ddis-11. Tti-2341: a Novel, Orally Bioavailable, Brain-penetrant, Covalent Epidermal Growth Factor Receptor (egfr) Inhibitor for Treatment of Glioblastoma Multiforme (gbm) and Brain Metastases of Non-small Cell Lung Cancer (nsclc)
2017 · Zezhou Wang, Peter Dove, et al. · Neuro-Oncology
Development of a proposed biosimilar product based on the demonstration of physicochemical, pharmacologic and clinical similarity to filgrastim.
2015 · Stephen Brokx, Kalpna Desai, et al. · Journal of Clinical Oncology
Report No. 7 of the Telecommunication Facility Siting Protocol Task Force
2013 · Tina Catalano, Michelle Vivar, et al.
Telecommunication Facility Siting Protocol Task Force
2013 · Tina Catalano, Mubarak Ahmed, et al.
Works count: 23
Citation count: 363
H-index: 8
I10-index: 7
Year
Topic
Type